Results 231 to 240 of about 470,839 (363)

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Interference-Free Measurement of Urinary Angiotensin-Converting Enzyme (ACE) Activity: Diagnostic and Therapeutic Monitoring Implications. [PDF]

Biomedicines
Szabó AÁ, Enyedi EE, Pintér TB, Mányiné IS, Váradi C, Bányai E, Tóth A, Papp Z, Fagyas M.   +8 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Angiotensin II and angiotensin converting enzyme: key players in the pathogenesis of hypertensive retinopathy. [PDF]

Rom J Ophthalmol
Pavlovschi E, Pantea V, Borovic D, Tagadiuc O.   +3 more
europepmc   +1 more source

Angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure in general practice in north Cumbria [PDF]

, 2000
Martin Toal, Robert D. Walker
openalex   +1 more source

Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? [PDF]

, 2001
McMurray, John J.V.
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Development of lisinopril radioconjugates for nuclear imaging of the angiotensin converting enzyme. [PDF]

Eur J Nucl Med Mol Imaging
Vaccarin C, Beyer D, Moiseeva A, Favaretto C, van der Meulen NP, Hunkeler BD, Rupp NJ, Marzaro G, Schibli R, Müller C.   +9 more
europepmc   +1 more source

Problems of measuring serum angiotensin converting enzyme in the RA-1000. [PDF]

, 1986
J E Buttery, B R Chamberlain
openalex   +1 more source

Use of glucagon‐like peptide‐1 receptor agonists in patients with left ventricular assist devices

ESC Heart Failure, EarlyView.
Key question: does GLP1‐RA therapy improve heart transplantation rates and clinical outcomes in patients with LVADs? Key findings: in this propensity score‐matched cohort study of 1068 LVAD recipients, GLP1‐RA use was associated with higher heart transplantation rates (18.9% vs.
Ramzi Ibrahim, Hoang Nhat, Mahmoud Abdelnabi, Beani Forst, Mohamed Allam, Xuan Ci Mee, Ghee Kheng Lim, George Bcharah, Timothy Barry, Juan Farina, Chadi Ayoub, Reza Arsanjani, Kwan Lee   +12 more
wiley   +1 more source